21595 ⎘
Preparations containing radioactive substances for use in therapy or testing characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus; Organic compounds; Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins; Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
FOXC1 ANTIBODIES AND METHODS OF THEIR USE
#302Anti-alpha5/beta1 antibody
#303Anti-CD19 antibodies
#304Immuno-conjugates and methods for producing them
#305Methods for identification of sites for IgG conjugation
#306PROCESS FOR CHELATING COPPER IONS USING CB-TE2A BIFUNCTIONAL CHELATE
#307Enantiomer-pure (4S,8S)- and (4R,8R)-4-p-Nitrobenzyl-8-methyl-3,6,9-triaza-3N,6N,9N-tricarboxymethyl-1,11-undecanedioic Acid and Derivatives Thereof, Process for their Production and Use for the Production of Pharmaceutical Agents
#308MISFOLDED PROTEINS IN CANCER TREATMENT AND DIAGNOSIS
#309PSMA antibodies and uses thereof
#310Class I anti-CEA antibodies and uses thereof
#311Anti-CD19 antibodies
#312SELECTIN LIGANDS USEFUL IN THE DIAGNOSIS AND TREATMENT OF CANCER
#313COMPOUNDS AND METHODS FOR THE DETECTION OF TRPV-6 CANCERS AND DRUG DELIVERY
#314Anti-CD74 immunoconjugates and methods of use
#315Antigen associated with the neovasculature of tumour metastases
#316Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications
#317Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
#318Cage-like bifunctional chelators, copper-64 radiopharmaceuticals and PET imaging using the same
#319Humanized L243 antibodies
#320Humanized anti-HLA-DR antibodies
#321SITE-SPECIFIC CONJUGATION OF LIGANDS TO NANOPARTICLES
#322DIAGNOSIS AND TREATMENT OF MALIGNANT NEOPLASMS
#323ZIRCONIUM-RADIOLABELED, CYSTEINE ENGINEERED ANTIBODY CONJUGATES
#324Anti-CD19 antibodies
#325Dual variable domain immunoglobulin and uses thereof
#326Structural variants of antibodies for improved therapeutic characteristics
#327Hexatriene-β-carbonyl compound
#328Radioactive material for inhibiting cancer and preparation method thereof
#329IMMUNOTHERAPY OF B CELL MALIGNANCIES AND AUTOIMMUNE DISEASES USING UNCONJUGATED ANTIBODIES AND CONJUGATED ANTIBODIES AND ANTIBODY COMBINATIONS AND FUSION PROTEINS
#330NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 158P1D7 USEFUL IN THE TREATMENT AND DETECTION OF BLADDER AND OTHER CANCERS
#331COMBINATORIAL THERAPY
#332Bifunctional polyazamacrocyclic chelating agents
#333MISFOLDED PROTEINS IN CANCER TREATMENT AND DIAGNOSIS
#334Monoclonal antibodies to tacrolimus and immunoassays methods for tacrolimus
#335Nucleotide and protein sequences of an antibody directed against an epitope common to human acidic and basic ferritins, monoclonal antibodies or antibody-like molecules comprising these sequences and uses thereof
#336Recombinant Peptides Derived from the Mc3 Anti-BA46 Antibody, Methods of Use Thereof, and Methods of Humanizing Antibody Peptides
#337METHODS FOR DETECTING PATHOLOGICAL SITES
#338Targeting of Erb Antigens
#339Bridgehead labelled compounds and methods of using the same
#340Anti-CD20 antibodies
#341Methods and Agents for Diagnosis and Prevention, Amelioration or Treatment of Goblet Cell-Related Disorders
#342Method for radiolabeling antibodies with yttrium-90
#343Diagnostic Imaging Compositions, Their Methods Of Synthesis And Use
#344Radioimmunoconjugates for targeted alpha therapy
#345Methods and therapies for treating inflammatory conditions with exposed collagen
#346Dual variable domain immunoglobulin and uses thereof
#347Medicament for the two-step perioperative therapy of solid tumours
#348Monoclonal antibodies to tacrolimus and immunoassay methods for tacrolimus
#349Humanized L243 antibodies
#350Cancer treatment kits using antibodies to aminophospholipids
#351Method to improve the efficacy of therapeutic radiolabeled drugs
#352Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof
#353Method for radiolabeling antibodies with yttrium-90
#354Methods and reagents for improving localization of treatment and visualization ligands to sites in a mammal
#355On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
#356PSMA formulations and uses thereof
#357Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
#358Methods and agents for diagnosis and prevention, amelioration or treatment of goblet cell-related disorders
#359Therapeutic application of chimeric and radiolabeled antibodies to human B Lymphocyte restricted differentiation antigen for treatment of B cell Lymphoma
#360Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
#361NSchelate-targeting ligand conjugates
#362Diagnosis and treatment of malignant neoplasms
#363Humanised antibodies and uses thereof
#364Methods and agents for diagnosis and prevention, amelioration or treatment of goblet cell-related disorders
#365IGF-1R monoclonal antibodies and uses thereof